8 completed. 8 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 8 |
| Phase 2 | 5 | Completed 5 |
Follow CLL: new trials by email Literature Review of CLL trials Research Report on CLL
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia Pitavastatin, Venetoclax - Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia | Phase 1 | Completed | University of California, Irvine | 6 | 2020-12-02 | 2025-09-11 |
| A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors CYT-0851, CYT-0851 in combination with gemcitabine, CYT-0851 in combination with capecitabine - Malignancy, Non-hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | Cyteir Therapeutics, Inc. | 169 | 2019-10-09 | 2024-12-24 |
| Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL Total Body Irradiation, Haploidentical Stem Cell Transplantation, CD56-Enriched Donor Lymphocyte Infusion - Multiple Myeloma, CLL | Phase 1 | Completed | Noah Merin | 20 | 2018-07-18 | 2024-11-12 |
| Obinutuzumab, High Dose Methylprednisolone (HDMP), and Lenalidomide for the Treatment of Patients With Richter's Syndrome Obinutuzumab, lenalidomide, HDMP - Richter's Syndrome, CLL | Phase 1 | Completed | University of California, San Diego | 4 | 2017-12-20 | 2022-07-05 |
| ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies Acalabrutinib, Pembrolizumab - Follicular Lymphoma (FL), CLL | Phase 1 / Phase 2 | Completed | Acerta Pharma BV | 161 | 2015-02-20 | 2026-05-13 |
| Fludarabine/Rituximab Combined With Escalating Doses of Lenalidomide in Untreated CLL Lenalidomide - CLL, Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Completed | Arbeitsgemeinschaft medikamentoese Tumortherapie | 12 | 2012-06-01 | 2016-05-26 |
| Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL veltuzumab - NHL, Lymphoma, Non-Hodgkin | Phase 1 / Phase 2 | Completed | Gilead Sciences | 32 | 2008-01-01 | 2021-08-16 |
| Phase I/II Study of Genasense in Patients With Chronic Lymphocytic Leukemia Oblimerson sodium, G3139 - Chronic Lymphocytic Leukemia, CLL | Phase 1 / Phase 2 | Completed | Genta Incorporated | 40 | 2001-01-01 | 2009-11-13 |
Leukemia, Lymphocytic, Chronic, B-Cell (6) · Lymphoma, Follicular (3) · Multiple Myeloma (3) · Neoplasms (3) · Hodgkin Disease (2) · Leukemia (2) · Lymphoma, Mantle-Cell (2) · Lymphoma, Non-Hodgkin (2) · Breast Neoplasms (1) · Bronchiolitis Obliterans Syndrome (1) · Burkitt Lymphoma (1) · Dendritic Cell Sarcoma, Interdigitating (1) · Head and Neck Neoplasms (1) · Leukemia, Hairy Cell (1) · Leukemia, Myeloid, Acute (1)
Hematologic Diseases (7) · Hemic and Lymphatic Diseases (7) · Immune System Diseases (7) · Immunoproliferative Disorders (7) · Lymphatic Diseases (7) · Lymphoproliferative Disorders (7) · Neoplasms by Histologic Type (7) · Chronic Disease (6) · Disease Attributes (6) · Leukemia, B-Cell (6) · Leukemia, Lymphoid (6) · Pathologic Processes (6) · Pathological Conditions, Signs and Symptoms (6) · Neoplasms (5) · Leukemia (4)
Bendamustine Hydrochloride (2) · Lenalidomide (2) · Rituximab (2) · Capecitabine (1) · Gemcitabine (1) · Whole-Body Irradiation (1) · acalabrutinib (1) · fludarabine (1) · fludarabine phosphate (1) · obinutuzumab (1) · oblimersen (1) · pembrolizumab (1) · pitavastatin (1) · veltuzumab (1) · venetoclax (1)
Acerta Pharma BV (1) · Arbeitsgemeinschaft medikamentoese Tumortherapie (1) · Cyteir Therapeutics, Inc. (1) · Genta Incorporated (1) · Gilead Sciences (1) · Noah Merin (1) · University of California, Irvine (1) · University of California, San Diego (1)
United States (7) · Austria (1)
Elizabeth Brem, MD (1) · Markus Renschler, MD (1) · Noah Merin, MD, PhD (1) · Thomas J. Kipps, M.D., Ph.D. (1) · William Wegener, MD, PhD (1)